News and price dashboard

Memory and AI infrastructure take the brunt

The day's damage is concentrated and it has one root cause. SanDisk is down 21.9%, the worst name on the list. The Investing.com piece, read in full, puts it on a second straight day of heavy selling across memory chips after Democrats took both chambers in Tuesday's midterms, with investors worried about tighter oversight of AI infrastructure and data center build-out, which is where SanDisk's NAND demand comes from. That demand produced $11.03 billion in quarterly revenue and a sixth consecutive earnings beat just last week. Three things piled on ahead of the election: Fox Advisors cut it from Overweight to Equal Weight on November 2 on near-term caution, Wells Fargo trimmed its price target, and Chief Legal Officer Bernard Shek sold 600 shares for roughly $695,000 under a pre-arranged 10b5-1 plan, routine but noticed. The article notes the stock has fallen a long way from its 52-week high of $2,354.39, with an 8-for-1 split still upcoming, and that the next Fed meeting isn't until December 8-9, so there's no monetary offset to the political uncertainty. Micron and Western Digital fell alongside it, which the piece frames as a sector repricing rather than anything SanDisk-specific. Separate headlines on SanDisk cover the same selloff, plus an ETF inflow note.

Astera Labs, cut targets against record revenue

Astera Labs is down 19.6%, and here the sector move had a company-specific edge. TD Cowen cut its target from $300 to $225 while keeping a Hold, and Needham went from $425 to $300 on valuation pressure across AI names. That came despite record Q3 2026 revenue of $584.9 million, up 154% year-over-year and ahead of guidance. A Form 144 filed today signals insider intent to sell, and it appears separately in your list as its own item. On the other side, BMO initiated at Outperform with a $375 target and Northland upgraded to Outperform at $315, both of which also show up as standalone headlines, and both of which the article says were simply swamped by the selling. The stock opened at $211.41, touched $178.06, and sits more than 63% below its 52-week high of $499.48. A TradingView post from Sam_mcmahon has it holding at a confluence of the 78.6% retracement and 88.7% downside extension in an ABC count, with the next mapped levels near $146 and $77 if that breaks. A headline-only item notes Astera guided fiscal Q4 revenue to $730-750 million on Tuesday.

The same trade across chips and networking

The rest of the semi and AI complex moved together: Credo down 18.1%, Micron 17.6%, AMD 17.3%, TSMC 11.1%, Arista 10.8%, Broadcom 10.5%. A TradingView note on Credo attributes its drop to the same midterm-driven worry about AI data center expansion and hyperscaler spending cycles, and maps a possible support area at $88.83 to $94.60. The Astera article adds that Qualcomm's weak smartphone chip earnings fed the rout, that the Philadelphia Semiconductor Index fell sharply, and that the Nasdaq closed down 5.3% with the S&P 500 off 4.2%. On AMD there's a Form 4 filing today with no detail given in the body, plus headlines noting HSBC raised its target to $540 while flagging a risk, and that shares fell despite a $17 billion revenue outlook. A TradingView post on Micron from VROCKSTAR argues the long case, that DRAM is constrained through 2028 in a three-player market and the implied multiple is far too low, and discloses a 40% long position in January 2028 70-delta calls. Nebius is down 15.0%, with a headline citing investors reassessing capacity delivery risk, and Vertiv down 14.3%.

Coherent sold off on good numbers

Coherent is down 13.6% despite what the headlines describe as strong Q1 fiscal 2027 results and a higher AI optics growth target. Fiscal Q2 2027 EPS guidance was set at $2.28 to $2.48 on November 4. Rosenblatt cut its target on lower multiples and Needham lowered to $340. Unusual option activity was flagged in COHR, BLK and AMAT. These are all headline-only, so the reason the stock went the other way isn't spelled out beyond the multiple compression point.

Datadog, a wall of lowered targets

Datadog is down 7.6% and carries the largest cluster of analyst notes in the list, all headline-only and all in the same direction: Wells Fargo to $300, Rosenblatt $285, Bernstein $273, RBC $270, DA Davidson $275, Cantor Fitzgerald $260, Evercore ISI $260, Barclays $262, Macquarie $240, StoneX $240, Wedbush $240. Several of the write-ups name guidance concerns as the reason.

SpaceX and the data center backlash

SpaceX is down 9.2% with a long run of headlines around it. They state a 6-gigawatt AI data center project drawing local pushback, banks testing demand for AI debt, lessors looking to sell a $40 billion AI deal, ARK buying the dip, proposed US space launch rule changes seen as a potential positive, China Renaissance initiating at $194.20, and Morgan Stanley at $300. Several tie the decline to post-midterm pressure on data center and merger outlooks alongside Tesla. Palantir is down 9.8%, with Cathie Wood buying $11 million on the dip.

Oracle loses a $7bn Tencent deal

Oracle is down 7.2%. Headlines state a $7 billion AI deal with Tencent was terminated, attributed to geopolitical pressure, with other items framing the move as investors weighing cloud growth against funding.

Earnings elsewhere

Eos Energy is down 12.2% after reporting Q3 revenue of about $82 million, described as record revenue and an earnings beat but still with losses, alongside an 8-K covering results and exit or disposal costs. Iovance is down 11.4% despite a record Q3 of roughly $122 million and narrower-than-expected losses. Revolution Medicines is down 11.2% even as Evercore ISI raised to $340, Guggenheim to $298, Truist to $261 and another firm to $222. Regenxbio is down 4.4% on a Q3 revenue miss and a $40.7 million net loss. Forgent Power Solutions is down 19.5%, and the only item on it is a pre-earnings options piece: Bloomberg-compiled options data implies an 11% move around the November 12 pre-market release, with the options market having called the size of the move in one of the last three reports. Joby is up 5.0% on advancing to the final FAA stage with revenue beating estimates, though Needham cut to $10 and Canaccord upgraded while cutting to $7. Sezzle is up 13.1%, with Needham raising to $220.

Quiet corners

Apple is down just 1.4% and most of its many items are ETF flow notes. The substantive ones are headline-only: a $7 billion bond offering for buybacks and other uses, and a report of reining in AI spending. IonQ, TeraWulf, Mercury Systems and SoundHound all hit 52-week lows; Exelixis and AbbVie hit all-time highs. The remainder of the list is routine ETF flow and filing items with nothing behind them worth your time.

Nurix down 38% on ARK buy and CFO sale

The biggest move on the list is Nurix Therapeutics, down 38.2%, and the two full-text items covering it don't explain the drop. ARK's daily trade file for Wednesday 4 November shows it bought 350,410 NRIX shares for $9,047,586 through ARKG, its largest purchase of the day. The same file shows the sale of 348,406 SpaceX shares across ARKK, ARKQ and ARKW for $49,233,251, plus sales of 46,164 Alphabet shares ($12,846,056) across ARKK and ARKQ, 8,551 Eli Lilly shares ($12,051,608) through ARKK, and 38,302 Personalis shares ($6,032,596) through ARKG. On the buy side it added 12,943 Twist Bioscience ($1,815,902), 73,281 Pacific Biosciences ($178,805) and 25,758 GeneDx ($1,768,029). One caveat worth knowing: the piece states it was AI-generated with editor review, and two commenters on the Investing.com version say ARK bought SpaceX rather than sold it, so the direction of that leg is disputed in the material itself. Separately, a headline-only GuruFocus item says Nurix CFO Houte Van sold 4,769 shares.

Modine off 21% after Q2 results

Modine is down 21.4%. The headline-only GuruFocus earnings call summary points to data centre revenue up 95%, and another headline-only item frames the 10-Q as showing strong growth potential, which sits oddly against the move. The one item here read in full was a Form 4 for Michael Bernard Mahan, President of Data Centers, dated 2 November, and the article carried nothing beyond the filing title, so there are no share counts or prices to report from it. Nothing in what was read explains the fall.

Ocugen, UroGen and Datadog

Three sizeable moves with headline-only coverage. Ocugen is up 17.4% on a headline saying its Phase III OCU400 gene therapy trials are advancing with top-line data expected in Q1 2027. UroGen is down 16.5% despite a headline citing a 35% sequential rise in Zysturi on the Q3 call. Datadog is down 14.4%, with only a 10-Q SWOT headline alongside it, and it also shows up as one of the day's biggest decliners on the Investing.com mover tables.

Eos Energy up 12.6% into its 8-K

Eos is up 12.6%. The 8-K filed 5 November covers Item 2.02 results of operations, Item 2.05 costs associated with exit or disposal activities, and Item 9.01 exhibits. The Investing.com version of that filing notice was read in full and contained no text beyond the headline, and the Nasdaq earnings page returned no data, so all that is confirmed is a results release before market open against a consensus of a 37 cent loss from four estimates, plus the fact that some kind of exit or disposal charge was disclosed alongside it. The content of either is not in the material.

Wheaton and AngloGold on gold strength

Wheaton Precious Metals is up 12.0% ahead of results due after the close, with consensus of 91 cents from five estimates. The Nasdaq page carried no actual figures. A separate headline-only GuruFocus item puts GF Value at $184.62 against a price of $131.50. AngloGold Ashanti is up 8.0% with results due before the open, one estimate at $1.70. Gold futures are quoted at 4,121.87, up 1.20% on the Investing.com tables in the articles read.

Sezzle up 11.6% on Q3 revenue of $166.5m

Sezzle is up 11.6%. The headline items state Q3 total revenue of $166.5 million and describe shares surging 24% on the result, with one GuruFocus headline also flagging valuation concerns. No further detail was read.

Kodiak Gas down 11.3%, with a stack of target cuts behind it

Kodiak is down 11.3%, and this one was read in full. CEO Robert McKee sold 2,666 shares on 3 November for $121,427, at $45.03 to $45.97, under a 10b5-1 plan adopted 19 May 2026. He directly holds 287,258 shares afterwards, with another 16,180 held indirectly through StarMac Investments. The article notes the stock has since fallen to $41.26, down 41% over six months, with a 4.75% dividend yield and three straight years of increases, and earnings scheduled for 9 November. On the analyst side it lists Stifel raising its target to $92 from $90 on revenue and adjusted EBITDA beating by 2.3% and 1.0% and demand for large horsepower compression, against four cuts: BofA to $74 from $83 on slower deal pacing in the power business, RBC to $82 from $88, Mizuho to $72 from $81 on a more back-weighted power deployment schedule, and Jefferies to $65 from $69 on limited near-term catalysts and timing risk. All four kept Buy or Outperform ratings. A separate headline says the Q3 dividend was raised by 4%, and there is a Regulation FD 8-K.

Envista, Intuitive, Navitas, Marathon

Envista is up 9.8% after what the headlines describe as a Q3 beat with raised guidance and core sales growth, with Needham keeping a Hold. Intuitive Surgical is up 9.4% against only a Form 144 filing. Navitas is up 9.0% after Rosenblatt upgraded it to Buy from Neutral. Marathon Petroleum is down 8.1%, tagged to a headline about Icahn Enterprises reporting a CVR Energy agreement to acquire refineries for roughly $4.2 billion.

Earnings reactions through the mid single digits

A thick cluster of names reported, all headline-only. AMC is up 7.3% on record Q3 revenue and a swing to profit, trading near a one-year high. Take-Two is up 7.1% with nothing behind it but ETF flow and GF Score notes. Dave is up 6.8%, though the headlines conflict: one cites record member growth and raised full-year guidance, another says shares dropped 7.8% on an earnings miss. Planet Fitness is down 6.4% after Q3 revenue of $360 million and GAAP EPS of $0.70 against an $0.79 consensus. Mineralys is up 6.3% on Phase 3 data and its Q3 update. Coherent is down 6.0% even though it beat by 11 cents on revenue above estimates and posted record Q1 revenue, guiding fiscal Q2 2027 EPS to $2.28 to $2.48; the analyst notes split, with Rosenblatt and Needham cutting targets (Needham to $340) and Stifel raising on the PhotonLink deal. Joby is up 4.1% on FAA certification progress and a raised revenue outlook, and Revolution Medicines is up 2.8% after launching RASONQUE with more than $198 million in initial US sales.

Chips and megacap tech split

Apple is up 5.3% at a record, with a cluster of ETF-flow headlines around it and one saying Apple is cutting its AI budget on cost control. Against that, Micron is down 7.0% on a headline about halting a Taiwan memory chip plant amid labour disputes, SanDisk is down 7.9%, and Astera Labs is down 4.4% after guiding fiscal Q4 revenue to $730 to $750 million and a UBS target cut to $290. AMD is only up 1.0% despite HSBC raising its target to $540 on server strength, with UBS lowering to $700 on a maintained Buy. Arista is up 5.0%, with a UBS target raise to $291 and a director sale of $829,255. SpaceX is down 3.8%, and the headlines around it run both ways: a Qualcomm partnership on Starlink mobile 5G and $40 billion of AI chip financing with Goldman Sachs and Apollo now in syndication, against the ARK selling story and several bearish chart posts.

The rest is quiet

Everything below that is routine: insider Form 4s at Recursion, Netflix, Neogen, Stagwell and SI-Bone, dividend declarations from UnitedHealth and Aflac, Oracle raising $20 billion in stock and notes, BWXT launching a $500 million senior notes offering, Costco's October net sales up 12.6%, Cognition Therapeutics receiving a Nasdaq deficiency letter alongside Q3 results, and a long tail of earnings-calendar entries with no numbers attached yet. Nothing there needs a look today.

Nurix down 38% after Sanofi scraps eczema partner drug

The biggest move on the list is Nurix, down 38.4%. Sanofi unexpectedly dropped the experimental atopic dermatitis drug the two were codeveloping, known as SAR448272 or NX-3911. Leerink's David Risinger, citing a Sanofi representative, said the reason given was "emerging nonclinical findings that did not warrant continued development in atopic dermatitis." Investor's Business Daily frames it as the two names diverging on the news. Two headline-only items sit alongside: Wells Fargo kept its rating and cut its target to $20, and a separate note that the shares slipped premarket on the halt of the STAT6 degrader trials.

Modine down 22% on earnings miss and guidance cut

Modine fell 22.3% and hit a 52-week low, touching $111.16 intraday and trading as low as $106.32 in the session. This was the first full session to react to fiscal Q2 2027 results released after the November 3 close. Adjusted EPS of $1.35 missed the $1.42 consensus, and gross margin narrowed 160 basis points to 20.7% on material cost inflation, tariff-related logistics costs, and inefficiencies from the fast build-out of data center cooling capacity. Updated FY2027 revenue guidance of $3.10bn to $3.20bn, which excludes the spun-off Performance Technologies segment, came in well under prior consensus. CEO Neil Brinker said supply chain and material cost impacts were "larger and are lingering longer than we had expected," and CFO Mick Lucareli pointed to the post-election environment and what it means for data centers. KeyBanc cut its target to $225 from $280 the same day while staying Overweight, saying the margin pressures look short-term and are already in the valuation, and expecting the production ramp to mature into fiscal 2028. For context on the rest of the Street, D.A. Davidson has reiterated Buy at $330, and consensus targets span $225 to $355. The stock is down 47.6% over six months and 61% from its $323.25 high, with a dividend yield near 12% on 36 straight years of payments. Separately, the company plans to rebrand as Modexus Solutions after the Gentherm merger and the Performance Technologies spinoff, subject to shareholder approval.

Ocugen up 17% on Q3 beat

Ocugen rose 17%. Third-quarter loss was $0.01 a share against a $0.06 consensus loss, and revenue of $1.95m beat the $1.08m forecast. The year-ago loss was $0.07. Operating expenses were roughly flat at $19.7m versus $19.4m, with R&D up to $12.5m and G&A down to $7.2m. Cash, restricted cash and short-term investments stood at $84.6m as of September 30, which CFO Rita Johnson-Greene said funds operations into 2028, enough to carry two of the three late-stage programs to BLA filing. All three programs are now in phase III. OCU400 finished enrollment in the phase III liMeliGhT trial with top-line data expected in Q1 2027, OCU410ST data is expected in Q2 2027, and OCU410 in geographic atrophy should finish enrollment in 2027 for a 2028 filing. The company also completed a MENA licensing deal for OCU400 and expects full Bahamas approval by year-end under the Longevity and Regenerative Therapies Act, priced to match US targets. An 8-K covering the results was filed, and there is a TradingView technical post on the name, which is one trader's chart view rather than company news.

Datadog down 14.5% despite a Q3 beat

Datadog fell 14.5%. Q3 revenue was $1.2bn, up 35.2% year over year, a $57m or 5% beat, with adjusted EPS of $0.81 against $0.64 expected and core growth accelerating for a fifth straight quarter into the high-20s percent range. The problem is the fourth-quarter outlook: management assumed only minimum commits from its largest customer, and several large early renewals cut unit pricing, which weighed on the sequential guide. Jefferies cut its target to $230 from $280 and stayed at Hold on that customer concentration, while saying it remains constructive on the underlying fundamentals. The rest of the note cluster points the same way, targets down but ratings kept: BTIG to $260, Rosenblatt to $285 from $305 on renewal headwinds, Needham holding $300, and Guggenheim reiterating Buy at $300 on AI-native contract growth. Several headlines put the drop at 18%.

UroGen off 16% on Q3 and an FDA acceptance

UroGen was down 16.3%. The headlines report Q3 revenue of $89m and FDA acceptance of the UGN-103 NDA, filed with an 8-K. No article was read in full, so there is nothing here on why the stock went the other way.

The post-midterm data center unwind

Several names moved against a strongly up market. The S&P rose about 1.6% to 1.8%, the Dow 3%, on relief that the midterms were resolved, with Democrats taking Congress. The Modine piece notes that data center infrastructure stocks sold off regardless, as Democratic gubernatorial wins raised concerns about restrictions on new data center development. That lines up with what the watchlist shows: Vertiv down 12.9% with notable option activity flagged, TeraWulf down 6.8% even on news that Google is providing credit support behind a $19bn Anthropic lease, Nebius down 6.7% with IBD headlining CoreWeave and Nebius sliding as the "blue wave clouds" the AI boom, and Generac off 9.5%. Only the headlines are available for those, so treat the connection as the one Modine's article draws, not a confirmed cause for each.

Other notable movers, headline only

Kosmos Energy fell 14.3% on a Q3 call that the headline says showed production up 14%. Envista rose 10% ahead of earnings framed around China headwinds. Upstart gained 9.4% while four firms cut targets, Morgan Stanley and Goldman both to $24, Truist to $30, B. Riley to $42. Navitas rose 9.3% on Q3 results and a Rosenblatt upgrade to Buy, though Needham trimmed its target to $15. Marathon Petroleum fell 8.5% even as Wells Fargo raised to $564 and Morgan Stanley to $458. BWXT fell 7.8% alongside a $500m senior notes offering to refinance debt and a Q3 call described as double-digit growth. Apple rose 5.2% to an all-time high at $351.74, with reports it is cutting engineers' daily AI spending budgets. Arista rose 4.4% after Q3, with targets moving both directions, Piper Sandler to $261, Truist to $240, Morgan Stanley to $230, against cuts from Barclays to $236 and Wells Fargo to $245. Astera Labs fell 5.4% after strong Q3, with most firms cutting targets. SpaceX fell 3.8% on the election outcome and Musk's failed bet, alongside a Qualcomm partnership for Starlink mobile. Everything below that is routine analyst maintenance and preview pieces without real movement behind it.

Xometry jumps on Q3 beat and raised guidance

Xometry is up 16.5%, the second biggest move on the list, and Wedbush lifted its target to $140 from $126 with an Outperform rating after the third quarter. Revenue was $252 million, up 40% year over year and roughly $16 million above the top end of guidance, with marketplace revenue up 43% to $238 million. Adjusted EBITDA of $21.4 million came in about 28% above consensus, margin went to 8.5% from 3.4% a year earlier, and the company posted its first quarter of positive GAAP net income at $1.9 million. Marketplace gross margin hit a record 36.0%, up 130bp sequentially, and it added a record 4,255 net buyers, with accounts spending $50,000 or more up 26%. Management raised full-year 2026 revenue growth guidance to about 37% from 33-34% and EBITDA to $68.0-68.5 million from $60-62 million. Citizens separately went to $135 from $120. The Siemens Design Center is still on track for a Q1 2027 beta. A GuruFocus SWOT piece on the 10-Q is also in the list, headline only.

TeraWulf and the Google-backed Anthropic project

TeraWulf is up 14.5% on news it executed credit support agreements with Google LLC for debt financing tied to roughly $19 billion of contracted lease commitments with Anthropic at the Justified Data Campus in Hawesville, Kentucky. Google's senior unsecured debt is rated AA+ by S&P and Aa2 by Moody's, which is the point of the arrangement: CFO Patrick Fleury said the investment-grade support improves the project's financing profile and its ability to pursue competitive long-term debt. TeraWulf also signed a definitive EPC agreement with Fluor Enterprises on a guaranteed maximum price basis covering three data center buildings, with phased ready-for-service completions starting late 2027 through Q2 2028. The company recently took contracted power at its Muskie campus in eastern Kentucky to 1 gigawatt. There is a matching 8-K filing in the list, and a TradingView technical post noting Q3 earnings are due Friday 6 November.

Navitas upgraded after high-power inflection

Navitas is up 7.9%. Rosenblatt upgraded it to Buy from Neutral with a $13 target against an $8.56 share price, saying the high-power strategy has hit an inflection: book-to-bill well above 1.0, backlog extending into mid-2027, and lower-value mobile and consumer revenue expected to approach zero entering 2027. Demand for efficient power systems, data centers in particular, is driving SiC and GaN adoption, and Rosenblatt sees the Claros acquisition as giving Navitas integrated voltage regulator technology for AI processor power management, with 2026-2027 design wins feeding 2028-2029 revenue. Context on the quarter itself: revenue of $13.99 million, up 38% year over year and 33% sequentially, above the $13.5 million consensus, but the loss of $0.14 per share was far wider than the $0.04 expected. Rosenblatt also noted the stock has fallen about 70% since June. Several headline-only items cover the same earnings call and results.

Oracle pulls the Tencent chip lease

Oracle is up 5.8%. Per the Financial Times, reported via Reuters and Investing.com, Oracle has cancelled its chip leasing contract with Tencent, estimated at $7 billion, after US officials approached the company with concerns. The deal was a five-year lease across Oracle data centers in Southeast Asia giving Tencent access to roughly 100,000 advanced AI chips otherwise unavailable in China. Tencent was pressured from the other direction too, with Guangdong officials asking it to support domestic chips. Reuters could not independently verify, and Oracle, Tencent and the White House did not comment. The same piece notes the FT reported Nvidia has told cloud clients they must sell at least 51% of capacity to non-Chinese companies, while ByteDance and Alibaba still hold large leasing deals with US providers.

Amphenol optical story after Q3

Amphenol is up 5.4%. Evercore ISI kept Outperform and a $100 target following the third quarter. Amphenol now expects its CCS unit to produce $5.1 billion of revenue and $0.18 of EPS contribution in 2026, up from $4.6 billion and $0.15 on a split-adjusted basis. Evercore puts the data-center optical portfolio at roughly a $5 billion run-rate, about half from CCS and half from core optical assets including FCI Asia, XGiga and Halo. Management expects CCS IT datacom sales to more than double in 2026 and reach about half of CCS revenue versus a third in 2025, with CCS running at low-20% EBIT margins against high-teens expectations on volume leverage and cost discipline rather than pricing. Amphenol is also buying Dexgreen, a European fibre-to-the-home supplier with about $90 million of sales, and Humanetics Sensors, a $70 million sensing business with fibre-optic sensing. The quarter itself was $0.80 adjusted EPS on $10.2 billion revenue against $0.72 and $9.44 billion expected, sales up 65%, orders a record $12.17 billion. Bernstein went to $102 from $99 and Goldman added it to its US Conviction List.

SanDisk insider sale against a volatile week

SanDisk is up 4.8%, and the news is an insider sale rather than anything operational. Chief Legal Officer Bernard Shek sold 600 shares on 2 November at $1,158.26, totalling $694,956, under a 10b5-1 plan adopted in March, leaving him with 24,666 shares directly. Worth noting the context the article gives: the stock was at $1,126.52, down nearly 20% over the prior week but up 479% over the year. December quarter guidance is for 12% revenue growth to $12.4 billion, just under the $12.5 billion consensus, with gross margin around 85.0%. Targets have been moving in both directions, Rosenblatt holding Buy at $2,400, Mizuho cutting to $1,900, Goldman and BofA both to $2,000, with Kioxia's warning about the NAND price surge ending cited as the broader worry.

AMD, the biggest cluster on the list

AMD is up 3.7% and dominates the item count, with roughly twenty headline-only pieces around the Q3 print. The direction of the notes is split: Stifel, Truist and Melius-style raises on data center strength, Jefferies reiterating Buy on server CPU growth and a separate item describing a Jefferies upgrade with a $650 target, Goldman reaffirming Buy at $700, against UBS cutting to $700 on valuation compression, Goldman lowering its target on valuation in another item, BofA cutting to $650 on sector multiple contraction, and Wells Fargo cutting. Northland stayed at Market Perform. Other headlines state Q4 revenue guidance of about $17.0 billion, a $1 billion quarterly charge tied to the OpenAI and Meta chip deals, and an AI collaboration with South Korea's government. I have only the headlines here, so the figures behind most of those targets aren't available to me.

Rocket Lab, insider selling and two target cuts

Rocket Lab is up 4.5% on a busy but headline-only set. Both Citizens and Evercore ISI cut price targets citing European competition. On the insider side, CFO Adam Spice sold $7.4 million of stock and director Nina Armagno sold 10,926 shares for $576,646, both filed for 2 November. Q3 results and the earnings call transcript appear in the list under the Neutron Holdings name, including a headline referencing revenue topping $1 billion.

Arista after earnings

Arista is up 3.5%. The headlines say the quarter beat and that the early 2027 revenue outlook came in above estimates. UBS, Melius and Rosenblatt all raised or reiterated on AI demand, while Wells Fargo cut its target on supply timing. Separately, 10% owner Andreas Bechtolsheim sold $45.8 million of shares, filed for 30 October.

SpaceX and the election unwind

SpaceX is listed up 3.6%, but the headlines point the other way: Investor's Business Daily and Investing.com both frame SpaceX and Tesla as sliding as Elon Musk's GOP election bet failed, with Morgan Stanley turning bullish in the same Investing.com piece. The Dow was up 800 points on the election result per IBD's live coverage. Treat the quoted move and the headline framing as being at odds, worth a direct look if you hold this.

Datadog's guidance problem

Datadog is up 2.0% on the quote, but the headlines describe earnings beating by $0.17 with revenue above estimates and the stock then tumbling 19% on a weak sales outlook, with a TradingView post flagging the flat Q4 guide. Again, the live quote and the headline narrative don't line up, so this one is worth checking directly.

Apple quiet on news, heavy on flows

Apple is down 1.9% with no single driver in the list. Bernstein raised its target to $380 on AI potential and Evercore ISI reiterated on the AI investment outlook, both headline only. The bulk of the remaining Apple items are GuruFocus ETF flow notes for 2 November showing SPY, IVV, QQQ, QQQM and XLK adding, with SPYV, SPXL and TECL selling.

Everything else worth a line

Vertex is down 4.0% with a Q3 call highlight headline citing revenue up 12% on CF. SI-Bone is up 17.6%, the largest move on the list, but the only item is a GuruFocus SWOT summary of the 10-Q flagging strong revenue growth alongside operating losses, so there's no stated reason for the move in the material. Astera Labs is up 1.7% after a record quarter with revenue up 154%, Northland upgrading and UBS cutting its target on valuation. BioCryst filed results in an 8-K, up 3.9%. Accenture is down 2.4% with a headline that its AI report is under scrutiny over fabricated citations. Citi cut Adobe, down 2.1%, citing the rising risk of a hard reset. Marathon Petroleum, down 0.7%, has a headline on selling refineries to CVR Energy in a $4.2 billion deal. Upstart drew target cuts from Mizuho and B.Riley on macro concerns, barely moving at +0.3%. Nurix carries a headline asking why the stock is collapsing 28% despite a listed +0.5%, another quote-versus-headline mismatch. TD Cowen downgraded Aurora Cannabis on the Organigram deal. Gold rose as the dollar weakened on the midterm results, per a GuruFocus headline on GLD. The remainder of the 200 items are routine ETF flow notes, Form 4s and SWOT summaries with nothing behind them.

SI-BONE jumps on Q3 beat despite a target trim

SIBN is up 17.6%, the biggest move on the list, and the Needham note read in full explains the setup. Needham actually cut its target to $26 from $27 while keeping a Buy, the cut driven by mix: procedure volume growth accelerated to 20% but roughly 5% of pricing headwind from procedure mix offset it. Q3 revenue was $55.7 million, up 15% year over year against a $55.3 million consensus, with an adjusted loss of 8 cents versus the 13-cent loss expected. Trailing twelve-month revenue was $220.65 million, up 14%, at a 79.4% gross margin, and management reiterated 2026 guidance. Needham flagged the recently cleared Onyx device as a possible lift to both case volume and revenue per procedure, alongside new launches, reimbursement and a wider commercial footprint. The same piece notes Canaccord Genuity at Buy with a $27 target on US surgeon engagement, and Citizens at Market Outperform with $32 citing 20% US volume growth. Separate headlines today show UBS raising to $26, TD Cowen raising to $23 on a maintained Buy, and Needham's cut to $26, so the target moves are going in both directions off the same quarter. There is also a Q3 earnings call highlights piece on the Onyx launch, headline only.

Xometry record quarter and first GAAP profit

XMTR is up 16.0% and hit an intraday all-time high of $117.50, with an earlier all-time-high print noted at $114.27. Q3 revenue was $252.4 million, up 40% year over year against roughly $235.5 million expected, and adjusted EPS of $0.28 beat the $0.19 forecast. The headline item is the first quarter of GAAP net income, $1.9 million, versus an $11.6 million loss a year ago. Marketplace revenue rose 43% to $238 million with marketplace gross margin at a record 36.0%, active buyers up 20% to 93,812 including a record 4,255 net adds, and adjusted EBITDA of $21.4 million at an 8.5% margin against 3.4% a year earlier. Management raised full-year guidance to about 37% revenue growth from 33-34% and adjusted EBITDA of $68-68.5 million, and guided Q4 to $254-256 million, above the $247.8 million consensus but implying deceleration to 32-33%. That deceleration is what drove an initial 7% pre-market drop and a roughly 4% decline in early trading before buyers took over. On the call, CEO Sanjeev Singh Sahni pointed to a $1 billion-plus revenue run rate and said the company has penetrated less than 1% of a $275 billion custom manufacturing market; CFO James Miln noted marketplace ad spend fell to a record-low 3.0% of marketplace revenue. Management flagged a deeper Siemens Designcenter integration with beta in Q1 2027 that should affect results from 2027. Cash and marketable securities stood at $505 million. The 8-K, the transcript and a record-quarter press release are also on the list.

Navitas into tonight's print

NVTS is up 8.4% ahead of third-quarter results due after the close. The preview read in full puts consensus at a 4-cent loss on $13.5 million of revenue, which would be about 34% revenue growth and a 59% narrowing of losses year over year. The stock was cited at $7.93 in the article, down 77% from a 52-week high of $34.17, with seven analysts at a neutral consensus and a mean target of $14.37. The focus is whether the October collaboration with Nvidia, a 24 kW 800V-to-12V power delivery board shown at OCP Global Summit 2026, is turning into volume orders, plus integration costs from the closed Claros acquisition and any guidance toward positive operating income. Trailing twelve-month diluted loss was $1.38 per share, annual revenue has contracted 46%, gross margin is 38%.

Oracle's $20 billion AI funding raise

ORCL is up 5.8% on a cluster of headlines about a $20 billion combined stock and bond offering to fund AI infrastructure, with the $10 billion equity portion priced at $116 and roughly 65% of it allocated to top investors. These are headline-only, so the detail stops there, but note the headlines conflict in tone: one asks why the stock is sliding, another cites a 4.31% gain, another frames the raise as exposing the cost of the AI build-out.

Tower Semiconductor, partnership plus target cuts

TSEM is up 5.1% on news of a collaboration with Innolight on near-package optics for AI, using 200mm and 300mm platforms. Alongside that, three target cuts came through on maintained positive ratings: Wedbush to $190, Susquehanna to $305, Stifel to $235 with Stifel's cut attributed to valuation. Cody Acree reiterated a Buy. All headline only.

Apple after earnings, and the memory cost thread

AAPL is down 1.9% and dominates the list by volume of items, almost all headline-only. The recurring theme is that a strong September quarter, with headlines citing record cash flow above $136 billion, was overshadowed by guidance for tightening margins and slowing services growth, with memory costs named repeatedly as the pressure on holiday-quarter margins. Analyst reaction split: JP Morgan lowered to $355, Morgan Stanley to $350, Baird raised to $340, DA Davidson raised on iPhone upgrades, Citi reaffirmed Buy at $365, Rosenblatt held at $303. One headline links Apple's memory warning to the Micron and SK hynix trade, which is worth noting against MU being up 2.7% today on its own "why is it rallying" piece. Separately Apple released a developer beta of iOS 27.3 and watchOS 27.3 with AI audio tools and China features, and updated App Store content descriptors ahead of new age rating rules.

Teva raises 2026 guidance

TEVA is up 3.0% after Q3 results with GAAP EPS of $0.20 and revenue around $4 billion, a revenue beat, raised 2026 guidance for key innovative brands, and continued debt reduction. Headline only, so no further detail on the drivers.

Marathon Petroleum results and the $4.2 billion refinery sale

MPC is essentially flat, down 0.5%, but carries a lot of news. Q3 EPS came in at $26.59 on about $56 billion of revenue, beating by $1.55, with record utilization driving EBITDA and a dividend increase. Alongside it, Marathon is selling refineries for $4.2 billion to Carl Icahn's CVR Energy, which has filed pro forma financials for the deal. All headline only.

Upstart, flat on a beat

UPST is unchanged at +0.1% despite a Q3 beat of $0.12 on EPS with revenue above estimates, record margins and a bank launch said to be nearing. Needham cut its target to $30 keeping a Buy, BTIG cut to $40.

Smaller movers and single-line items

IOVA is up 9.8% with UBS raising its target to $8. NBIS is up 7.4% with a "why is it rallying" piece, headline only, so the reason isn't available here. SEZL is down 4.6% with nothing behind it but two bare TradingView tickers. SPCX is up 3.8% on continuing Tesla merger talk headlines, including one on Musk's pay under a combined entity. COHR up 3.6% on an AI data center demand piece. ANET up 3.4% ahead of earnings with a roughly $3.3 billion revenue test flagged. AVGO up 3.2%, one headline tying it to Anthropic leases at a $161.2 billion payment scale. AMC up 3.1% ahead of Q3. Axsome, up 2.7%, drew five target revisions in a single day, Morgan Stanley up to $249 and UBS, RBC, Guggenheim and Baird all down, to $239, $273, $250 and $220. Accenture is down 2.5% with a "why is it sliding" headline and no explanation available. Beam Therapeutics, up 1.7%, reported a Q3 net loss of $134.4 million on revenue well below expectations. PayPal, down 0.9%, was downgraded by Freedom Broker on valuation, with a separate headline noting Michael Burry sees it doubling. Aurora Cannabis is being acquired by Organigram for C$561 million in cash and stock. Wedbush initiated SMR at Underperform. The rest of the list is ETF flow notices, Form 4 filings and bare chart posts with no substance.

Oracle's $20bn raise lands badly

Oracle is the main event, down 8.8%. The company priced concurrent equity and debt offerings late Monday: 86.2 million shares at $116, roughly an 11% discount to the October 30 close, plus $10 billion of new senior notes with maturities from two to twenty years. The money is earmarked for AI and cloud infrastructure buildout, but the structure of it is the problem. Oracle had pledged at its Investor Day just five days earlier to cap fundraising at $20 billion for the fiscal 2027-2030 cycle, and it used the entire ceiling in one transaction. New shares dilute, and the notes add to a debt load already around $125 billion at the last fiscal year end. Moody's assigned the new notes a Baa2 rating and kept its negative outlook. Not all one way: Stephens upgraded to Overweight with a $213 target, citing improved evidence on capital intensity and higher free cash flow projections, and BNP Paribas stayed bullish at $248. Investing.com notes the S&P was essentially flat while this happened, so the pressure is company-specific rather than sector-wide, and the stock is near its 52-week low of $114.50 with the $116 offering price now acting as a watched level. A separate TradingView chart post from Badcharts simply flags Oracle as down over 60% from its last peak. Half a dozen other headlines in the list cover the same offering from different angles.

Kosmos leads the decliners

KOS is down 13.3%, the biggest move in the section, but the only item is a headline-only GuruFocus SWOT piece drawn from the 10-Q. Nothing here explains the drop, so if you hold it, that one needs a look elsewhere.

Upstart beats but guides below

Upstart is down 7.4% despite a Q3 beat: EPS of $0.33 against a $0.21 estimate, revenue $370.52 million versus $365.86 million consensus. The guidance is the likely issue. The company sees FY2026 revenue of $1.32 billion against analyst consensus of $1.42 billion. The stock closed at $21.31 before this, already down 31% over three months and 54% over twelve, and had four negative EPS revisions against one positive in the last 90 days. The 8-K is filed.

Mid-sized decliners with thin coverage

Tower Semiconductor is down 6.7% and TD Synnex down 6.1%, both with only GuruFocus valuation-screen headlines attached and no explanation. Axsome is down 5.8%; Baird kept its rating but cut its target to $220, and the Q3 call headline flags revenue crossing a $1 billion run rate. Micron is down 5.8% with nothing behind it but an ETF flow note. Iovance is off 5.4% alongside a headline reporting a 24.6% objective response rate in the Phase 2 IOV-LUN-202 trial with an sBLA planned for 2027. Rocket Lab is down 4.9% with a Form 144 filed. NuScale is down 4.8% after Wedbush initiated coverage at Underperform. On the up side, On Holding is up 5.2% with only a BTIG reiteration at $60 in the list.

SI-BONE and Nurix, insider selling on both

SI-BONE is down 4.8% on a heavy news day: 15% revenue growth in Q3, full-year guidance reaffirmed, Needham cutting its target to $26 on pricing mix, Canaccord reiterating on surgeon growth, and SVP Michael Pisetsky selling $655,744 of stock. Nurix is down 4.1% with three executives selling on October 30: CFO Hans van Houte $74,474, chief legal officer Christine Ring $103,986, and CSO Gwenn Hansen $142,899. No other news on Nurix in the list.

Marathon Petroleum selling refineries

MPC is down 3.2%. Q3 earnings beat by $1.55 with revenue well above estimates, and multiple headlines report CVR Energy nearing or agreeing a deal to buy Marathon refineries for roughly $4.2 billion. Board changes at both MPC and MPLX are also filed. Teva is down 3.3% with Q3 results in an 8-K and the election of Dr. David J. Brailer to the board effective today.

Apple down 1.8% on margin guidance, and the knock-on

Apple is only down 1.8% but it's the source of today's broader tech weakness, with headlines explicitly tying the European share slide and the Asia session to Apple's margin warning. The pattern across the coverage: a record September quarter and record Greater China revenue, offset by rising memory costs and a cautious holiday outlook from CEO John Ternus, plus Services deceleration. The analyst reaction splits. Baird raised to $340, Citi reaffirmed Buy at $365, Bernstein reiterated Outperform at $370, Evercore ISI and Melius both stayed positive, while Morgan Stanley cut to $350 and Aletheia Capital reiterated Sell on margin concerns. Apple suppliers in Asia are reported as split for the same reason, strong iPhone sales against memory cost inflation. One caveat on this section: a very large number of items tagged AAPL are routine BlackRock 13F and ETF-flow posts from GuruFocus with nothing to do with Apple itself. They're noise.

Smaller movers and quiet names

PayPal is up 3.1% on a headline that Michael Burry sees it doubling or more. Intuit up 3.2%, Paychex up 3.0% crossing above its average analyst target, Costco up 2.8%, Avery Dennison up 2.6%, all with only screen or chart headlines behind them. CRISPR is down 2.8% with Needham holding at $82 and Citizens reiterating on Casgevy sales. Xometry is up 2.0% after beating by $0.09 with revenue above estimates. Everything below that, including Broadcom, Accenture, Adobe, Netflix, BWXT and Itau, is essentially flat with routine filings, ETF flow notes and valuation screens attached.